Effects of lithium carbonate on methylphenidate-induced mood, behavior, and cognitive processes

Huey, Leighton Y.; Janowsky, David S.; Judd, Lewis L.; Abrams, Alan; Parker, Donal C.; Clopton, Paul

doi:10.1007/bf00429209

Cited by 40 publications

(15 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a double-blind study of depressed patients, the euphoriant and/or activating effects of amphetamine were also either attenuated or blocked by lithium (Van Kammen and Murphy, 1975). Other double-blind studies have shown the same effect of lithium on schizophrenic patients treated with amphetamine (Van Kammen et al, 1985), as well as on patients with a variety of other psychiatric illnesses (Huey et al, 1981).…”

Section: Lithium and Stimulants In Humansmentioning

confidence: 89%

The behavioral actions of lithium in rodent models: Leads to develop novel therapeutics

O’Donnell

Gould

2007

Neuroscience & Biobehavioral Reviews

121

View full text Add to dashboard Cite

For nearly as long as lithium has been in clinical use for the treatment of bipolar disorder, depression, and other conditions, investigators have attempted to characterize its effects on behaviors in rodents. Lithium consistently decreases exploratory activity, rearing, aggression, and amphetamine-induced hyperlocomotion; and it increases the sensitivity to pilocarpine-induced seizures, decreases immobility time in the forced swim test, and attenuates reserpine-induced hypolocomotion. Lithium also predictably induces conditioned taste aversion and alterations in circadian rhythms. The modulation of stereotypy, sensitization, and reward behavior are less consistent actions of the drug. These behavioral models may be relevant to human symptoms and to clinical endophenotypes. It is likely that the actions of lithium in a subset of these animal models are related to the therapeutic efficacy, as well the side effects, of the drug. We conclude with a brief discussion of various molecular mechanisms by which these lithium-sensitive behaviors may be mediated, and comment on the ways in which rat and mouse models can be used more effectively in the future to address persistent questions about the therapeutically relevant molecular actions of lithium.

show abstract

Section: Lithium and Stimulants In Humansmentioning

confidence: 89%

The behavioral actions of lithium in rodent models: Leads to develop novel therapeutics

O’Donnell

Gould

2007

Neuroscience & Biobehavioral Reviews

121

View full text Add to dashboard Cite

show abstract

“…The hyperactivity is attenuated by antipsychotic drugs as well as anticonvulsants often utilized for the treatment of bipolar disorder (Lamberty et al, 2001). It also has validity in the sense that amphetamine commonly precipitates manic episodes in susceptible individual who suffer from bipolar disorderFan effect that may be attenuated by lithium (Huey et al, 1981;van Kammen et al, 1985;Van Kammen and Murphy, 1975). Further, the motoric changes in activity present in bipolar disorder are among the most defining characteristics of the illness, ranging from near catatonic immobility to the profound hyperactivity of manic states.…”

Section: Recent Support From Animal Behavioral Models and Genetic Stumentioning

confidence: 99%

Glycogen Synthase Kinase-3: a Putative Molecular Target for Lithium Mimetic Drugs

Gould

Manji

2005

Neuropsychopharmacol

341

253

View full text Add to dashboard Cite

“…The use of dopaminergic stimulants has been associated with the onset of mania in bipolar patients and with manic-like symptoms in control subjects (Anand et al, 2000;Mamelak, 1978;Murphy et al, 1971;Peet and Peters, 1995). Some studies report that lithium can attenuate or prevent the behavioral and/or functional effects of dopaminergic drugs Huey et al, 1981;Silverstone et al, 1998;van Kammen et al, 1985;Van Kammen and Murphy, 1975;Willson et al, 2005). These data have led to the suggestion that how the human brain responds to dopaminergic stimulants may be a clinical endophenotype of bipolar disorder (Hasler et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

Strain Differences in Lithium Attenuation of d-Amphetamine-Induced Hyperlocomotion: A Mouse Model for the Genetics of Clinical Response to Lithium

Gould

O’Donnell

Picchini

et al. 2006

Neuropsychopharmacol

109

View full text Add to dashboard Cite

Lithium attenuation of stimulant-induced hyperlocomotion is a rodent model that may be useful both to understand the mechanism of the therapeutic action of lithium and to develop novel lithium-mimetic compounds. To lay the foundation for future investigations into the neurobiology and genetics of lithium as a therapeutic agent, we studied the effect of lithium on d-amphetamine-induced hyperlocomotion in 12 (3 outbred) mouse strains. In our initial screening, mice received either (1) no drugs, (2) LiCl only, (3) damphetamine only, or (4) d-amphetamine and LiCl. Whereas there was no significant effect of LiCl alone on locomotion in any strain, there was a large degree of strain variation in the effects of LiCl combined with d-amphetamine. LiCl attenuated d-amphetamine-induced hyperlocomotion in C57BL/6J, C57BL/6Tac, Black Swiss, and CBA/J mice, whereas CD-1, FVB/NJ, SWR/J, and NIH Swiss mice, which were responsive to d-amphetamine, showed no significant effect of LiCl. d-Amphetamine-induced hyperlocomotion in the C3H/HeJ strain was increased by pretreatment with lithium. A subset of strains were treated for 4 weeks with lithium carbonate before the damphetamine challenge, and in each of these strains, lithium produced effects identical to those seen following acute administration. Strain responsiveness to lithium was not dependent upon the dose of either d-amphetamine or LiCl. Further, the results are not explained by brain lithium levels, which suggests that these behavioral responses to lithium are under the control of inherent genetic or other biological mechanisms specific to the effects of lithium on brain function.

show abstract

Effects of lithium carbonate on methylphenidate-induced mood, behavior, and cognitive processes

Cited by 40 publications

References 22 publications

The behavioral actions of lithium in rodent models: Leads to develop novel therapeutics

The behavioral actions of lithium in rodent models: Leads to develop novel therapeutics

Glycogen Synthase Kinase-3: a Putative Molecular Target for Lithium Mimetic Drugs

Strain Differences in Lithium Attenuation of d-Amphetamine-Induced Hyperlocomotion: A Mouse Model for the Genetics of Clinical Response to Lithium

Contact Info

Product

Resources

About